Abstract-Left ventricular (LV) hypertrophy, a marker for adverse cardiovascular events, is more common in blacks than in non-Hispanic whites. Mechanisms leading to LV hypertrophy and mediating its clinical sequelae in blacks are not fully understood.
T he prevalence of hypertension among blacks in the United States is among the highest in the world, and it continues to increase. 1 Furthermore, hypertension-related mortality rates are 3 times higher in black (49%) compared with non-Hispanic white men (16%) and more then double in black (37%) compared with non-Hispanic white women (14%). 1 Hypertensive blacks are more likely to develop targetorgan damage than their non-Hispanic white counterparts, including left ventricular (LV) hypertrophy (LVH), 2 renal failure, 3 and stroke. 4 The prevalence and severity of hypertension tend to be higher in blacks than non-Hispanic whites, 1 and LVH is more often present in blacks despite similar blood pressure levels and hypertension duration. 2 Furthermore, LVH is an important prognostic factor in hypertensive individuals, and the association of LVH with mortality is even more pronounced in blacks than in other ethnic groups. 5 Given the higher prevalence of LVH and the associated poor prognosis in blacks, identifying biological pathways that contribute to the pathogenesis and clinical sequelae of LVH in this ethnic group is important. Such knowledge may have significant clinical and therapeutic implications, including detection of individuals at risk. We hypothesized that biomarkers in pathways of inflammation, hemodynamic stress, lipoprotein metabolism, insulin resistance, and calcification are associated with LVH in blacks. To this end, we investigated the associations of 39 candidate biomarkers in these pathways with LV mass and LV remodeling/geometry in a cohort of blacks without a history of myocardial infarction or stroke.
Methods

Study Participants
Study participants were part of the Genetic Epidemiology Network of Arteriopathy Study, a community-based study aimed at identifying genetic variants influencing blood pressure (BP) levels and the development of target organ damage attributed to hypertension. 6 Participants were ascertained from sibships in which Ն2 family members were diagnosed with hypertension before the age of 60 years. Between December 1, 2000, and October 31, 2004 , 1324 black participants from Jackson, Mississippi, completed the study protocol. We excluded 131 participants with history of myocardial infarction or stroke, and the remaining 1193 participants were included in the final analysis. The project was approved by the University of Mississippi Institutional Review Board, and participants gave informed consent.
Assessment of Baseline Characteristics
Information about the participant baseline characteristics, medical history, medications, and demographics was obtained from a comprehensive questionnaire administered on the day of the study by trained staff, as described previously. 7 Race was self-reported. Hypertension was defined as a systolic BP Ն140 mm Hg or diastolic BP Ն90 mm Hg at the study visit or report of a previous diagnosis of hypertension and current treatment with antihypertensive agents. Diabetes mellitus was considered present if a participant was being treated with insulin or oral agents or had a fasting glucose level Ն7.0 mmol/L (126 mg/dL). "Ever " smoking was defined as having smoked Ͼ100 cigarettes in the past. Weight was measured in kilograms by an electronic scale, and height was measured in centimeters by a stadiometer.
Assessment of LVH
We used echocardiographically derived LV mass index (LVMi) as the measure of LVH. 2D and Doppler echocardiography were performed in the left lateral decubitus position on an Acuson 128XP/10c machine (Acuson, Malvern, PA) using 2.5-, 3.5-, and 5.0-MHz transducers, and LV wall thickness and dimensions were measured as described previously. 8 2D left atrial diameter and LV ejection fraction were obtained from the parasternal long axis view. LV mass was derived from the simplified cubed equation formula 9 and indexed to height 2.7 to normalize heart size to body size (LVMiϭLV mass/height 2.7 ). 10 Increased LVMi was defined as LVMi Ͼ44 g/m 2.7 in women and LVMi Ͼ48 g/m 2.7 in men. 11 Relative wall thickness (RWT) was calculated as the sum of LV septal and posterior wall thickness at end-diastole divided by LV internal dimension at end diastole. A RWT Ͼ0.42 was used to define increased RWT in men and women. 11 Patterns of LV geometry were defined as follows: (1) normal: normal LVMi and normal RWT; (2) concentric remodeling: normal LVMi and high RWT; (3) concentric hypertrophy: high LVMi and high RWT; and (4) eccentric hypertrophy: high LVMi and normal RWT.
Circulating Biomarkers
Thirty-nine candidate biomarkers representing pathways of inflammation, hemodynamic stress, lipoprotein metabolism, insulin resistance, and vascular calcification were measured in plasma or serum. 12 The biomarkers and the corresponding abbreviations are listed in Table 1 . Assays for the individual biomarkers, including precision, accuracy, and stability, as well as methods for quality control, have been described previously in detail. 12 
Statistical Methods
The mean levels of the significant biomarkers across the 4 patterns of LV geometry were compared with 1-way ANOVA. Biomarkers levels and LVMi were log-transformed to reduce skewness. We used linear regression to assess the associations of each of the 39 biomarkers with LVMi after adjustment for age and sex (model 1); after further adjustment for potential confounders (hypertension, diabetes mellitus, weight, smoking, total and high-density lipoprotein cholesterol, estimated glomerular filtration rate, and use of aspirin, statins, estrogens, and antihypertensives; model 2); and additional adjustment for LV ejection fraction and left atrial diameter (model 3). Regression analyses were performed using generalized estimating equations to account for potential correlation among siblings in the sample. Model selection was performed using a "forward" approach with criteria of PՅ0.10 to enter and PՅ0.05 to stay in the model. We then created a separate multivariable model that included all of the significant biomarkers, while adjusting for the above covariates. Similar analyses were also performed in the subset of hypertensive individuals (nϭ936). To reduce the possibility of type I error caused by multiple testing, we used the Bonferroni correction, and a P value Յ0.001 (0.05Ϭ39, because we analyzed 39 different biomarkers) was considered to be statistically significant.
In addition, multivariate logistic regression was used to assess the associations of each significant biomarker with the presence of LVH and each of the 3 patterns of abnormal LV geometry, after adjustment for covariates in models 2 and 3 above. For these analyses, adjusted odds ratios (ORs) and 95% CI for 1 logarithmic unit increase in biomarker levels were calculated. A P value Յ0.01 was considered statistically significant (0.05Ϭ5, because only 5 biomarkers were assessed at this level) for the logistic regression analyses.
To assess the discriminatory power of various statistical models for predicting the presence of LVH and each abnormal LV geometry pattern, we calculated the c-statistic for models that included the following: (1) age and sex; (2) age, sex, and significant biomarkers; and (3) age, sex, and conventional risk factors (hypertension, diabetes mellitus, systolic and diastolic BP, weight, smoking, total and high-density lipoprotein cholesterol, and estimated glomerular filtration rate); and (4) age, sex, conventional risk factors, and significant biomarkers. The incremental value of adding the significant biomarkers to conventional risk factors for predicting the presence of LVH was evaluated with the net reclassification index, as described previously. 13 Statistical analyses were performed with SAS version 9.0 (SAS Institute Inc, Cary, NC).
Results
The baseline characteristics of the study participants are described in Table 2 . The distributions of the 39 candidate biomarkers are summarized in Table S1 (available in the online Data Supplement at http://hyper.ahajournals.org).
After adjustment for age and sex, higher levels of the following biomarkers were associated with greater LVMi: C-reactive protein, interleukin 6, E-selectin, leptin, resistin, N-terminal (NT)-pro-brain natriuretic peptide (BNP), midregional (MR)-pro-atrial natriuretic peptide (ANP), carboxyterminal (CT)-pro-arginine vasopressin, MR-proadrenomedullin (ADM), CT-pro-endothelin (CT-proET), and osteoprotegerin (OPG; Table 3 ). After further adjustment for potential confounders, higher NT-proBNP, MR-proANP, 
Coutinho et al Biomarkers of Left Ventricular Hypertrophy
MR-proADM, CT-proET, and OPG remained independently associated with greater LVMi (Table 3 ). The associations of NT-proBNP, CT-proET, and OPG with LVMi were independent of LV ejection fraction and left atrial size (Table 3) . Lastly, in the multivariable model that included all of the significant biomarkers, higher NT-proBNP (␤ϮSE: 0.06Ϯ0.01; PϽ0.0001) and OPG (␤ϮSE: 0.06Ϯ0.02; Pϭ0.0013) remained independently associated with greater LVMi. When hypertensive participants were analyzed separately (nϭ936), similar results were observed (Table S2 ). The levels of all 5 of the biomarkers associated with LVMi were higher among participants with concentric hypertrophy than in participants with other LV geometric patterns ( Figure S1 ; P value for trend Ͻ0.0001 for each of the 5 biomarkers ) were also associated with the presence of eccentric hypertrophy after adjustment for age, sex, and other confounders but not after adjustment for left atrial size and ejection fraction. None of the biomarkers were independently associated with concentric remodeling or concentric hypertrophy. These analyses may not have adequate power given the low number of participants in these groups.
The discriminatory power of various models to predict LVH is summarized in Table 4 . Adding the 5 significant biomarkers to age, sex, and conventional risk factors improved the prediction of LVH and each abnormal LV geometry pattern. The net reclassification index for the multivariable models that included the 5 significant biomarkers was 10.5% (Pϭ0.007).
Discussion
The main finding of our study is that higher levels of vasoactive peptides (NT-proBNP, MR-proANP, MRproADM, and CT-proET) and OPG were independently associated with greater LVMi in blacks. The addition of these 5 biomarkers to age, sex, and conventional risk factors improved the ability to discriminate between those with and without LVH. The associations of these biomarkers with LVMi appeared to be driven by their associations with eccentric hypertrophy. The absence of an independent association of the biomarkers with concentric hypertrophy may be because of the small number of participants (22 of 1193) who had this LV geometric pattern. To the best of our knowledge, our study is the first to use a multimarker approach in the study of LVH and adverse LV remodeling in blacks. Our findings are relevant for understanding potential pathophysiologic mechanisms associated with LVH and adverse LV remodeling in this ethnic group.
Hemodynamic Stress and LVH
Higher circulating levels of 4 markers of hemodynamic stress, NT-proBNP, MR-proANP, MR-proADM, and CTproET, were independently associated with greater LVMi and presence of LVH in blacks. Furthermore, NT-proBNP, MRproANP, and CT-proET were associated with the presence of eccentric hypertrophy. Although the associations of BNP and its precursors with LVMi and LVH have been reported previously, our study is the first to focus on a black cohort. BNP, ANP, or related precursors appear to be stronger predictors of LVH in higher-risk populations 14 -17 than in the general population. 18, 19 Similar to results from our study, levels of BNP were also higher among individuals with concentric hypertrophy in the Framingham Offspring Study. 20 In contrast, in studies of elderly men (age Ն70 years), NT-ANP 21 and -BNP 22 levels were the highest among those with eccentric hypertrophy. The clinical use of BNP and NT-proBNP in hypertensives appears to go beyond prediction of LVH, because these markers are also associated with an adverse prognosis independent of LVH, 23 highlighting the potential use of the natriuretic peptides for identifying blacks at higher risk of adverse cardiovascular events. The natriuretic peptides offset the deleterious effects of volume overload by improving myocardial relaxation and counteracting the sodium restriction and vasoconstriction promoted by the renin-angiotensin-aldosterone system. 24 In the setting of hypertensive heart disease, increased wall stress attributed to myocardial hypertrophy and pressure overload and elevated LV filling pressures may lead to ventricular and atrial production of ANP and BNP, thereby promoting vasodilation, diuresis, and natriuresis to offset the deleterious effects of LVH and its hemodynamic consequences. 25 Contemporary studies in patients with heart failure suggest that the assays commonly used to quantify circulating BNP and NT-proBNP also capture forms of the peptide that are not biologically active, 26 introducing the concept of BNP dysfunction/resistance. We can speculate that reduced biological activity of the natriuretic peptides in pathological conditions, such as heart failure and LVH, may lead to decreases in the compensatory natriuresis and vasodilation, resulting in increased production of NT-proBNP and MR-proANP. However, additional studies are required to prove this hypothesis.
Two previous studies found higher adrenomedullin levels to be associated with LV mass in humans, 27, 28 but this is the first report of associations of adrenomedullin with patterns of LV remodeling. Adrenomedullin, a peptide abundantly expressed in cardiovascular tissues, 29 reduces peripheral arterial resistance and BP. 30 In animal models, adrenomedullin levels increased with LV mass after aortic banding, 31 whereas in CRP indicates C-reactive protein; IL, interleukin; NT-proBNP, N-terminal pro-brain natriuretic peptide; MR-proANP, mid-regional pro-atrial natriuretic peptide; CT-proAVP, C-terminal pro-arginine vasopressin; MR-proADM, mid-regional pro-adrenomedullin; CT-proET, C-terminal pro-endothelin; OPG, osteoprotegerin. A P-value Յ0.001 was considered statistically significant. *Model 1 was adjusted for age and sex. †Model 2 was adjusted for age, sex, hypertension, diabetes mellitus, smoking history, weight, total cholesterol, high-density lipoprotein cholesterol, estimated glomerular filtration rate, and use of aspirin, statins, estrogens, ␤-blockers, calcium channel blockers, diuretics, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. ‡Model 3 was adjusted for the same variables as model 2, plus left ventricular ejection fraction and left atrial size. NT-proBNP indicates N-terminal pro-brain natriuretic peptide; MR-proANP, mid-regional pro-atrial natriuretic peptide; MR-proADM, mid-regional proadrenomedullin; CT-proET, C-terminal pro-endothelin; OPG, osteoprotegerin; LVH, left ventricular hypertrophy.
*Conventional risk factors included in the models were as follows: history of hypertension, diabetes mellitus, and smoking; weight; total and high-density lipoprotein cholesterol; estimated glomerular filtration rate; and systolic and diastolic blood pressures.
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salt-sensitive hypertensive rats, adrenomedullin gene delivery resulted in sustained decreases in BP and LV mass. 32 Elevated adrenomedullin levels may, therefore, represent a compensatory mechanism aimed at lowering BP and preventing LV remodeling in the setting of hypertension. The potential of adrenomedullin as therapy for hypertension and LVH needs further investigation. We previously reported CT-proET to be independently associated with LVMi, 8 and similar findings were also observed by Hua et al. 33 In contrast, no significant association was present in the Losartan Intervention for Endpoint Reduction substudy. 34 Endothelin, an endothelium-derived peptide, is one of the most potent vasoconstrictors known, and its production is stimulated by angiotensin II in vivo. 35 Potential mechanisms linking CT-proET to LVH have been reviewed. 8 It is possible that the association of CT-proET with LVMi may be in part attributed to its adverse hemodynamic effects 35 and also a direct role in myocyte hypertrophy. 36 Whether endothelin receptor blockade attenuates or prevents development of LVH in hypertensives merits further investigation.
In summary, elevations of NT-proBNP, MR-proANP, and MR-proADM levels may represent compensatory mechanisms aimed at lowering BP and preload and decreasing LV mass, whereas elevated CT-proET may promote development of hypertension and LVH. It is possible that the associations we found are due to hemodynamic effects of LVH rather than being specific to blacks. The cross-sectional nature of our study does not allow us to make inferences regarding the causality or temporality of the associations.
OPG and LVH
OPG was independently associated with LVMi and the presence of LVH in blacks. Although OPG levels were highest among individuals with concentric hypertrophy, OPG was not independently associated with concentric LVH, likely because of the low number of participants with concentric LVH (22 of 1193). We have previously reported OPG to be independently associated with LVMi in 898 hypertensive blacks. 37 de Lemos et al 19 studied 2715 subjects (mean age: 44 years) with a low prevalence of hypertension and found that OPG was independently associated with LVMi in men but not in women. In 100 patients with coronary artery disease, OPG was correlated with increased LVMi but not after adjustment for age. 38 OPG has been shown to be associated with cardiovascular diseases 39, 40 ; however, our observation of an independent association of OPG with LVMi and eccentric hypertrophy is novel. Potential mechanisms linking the OPG/receptor activator of nuclear factor B ligand system to LVH have been reviewed. 37 The results from our study motivate further investigation to elucidate the pathophysiologic basis of the association of OPG with LVH in blacks and the potential use of OPG as a marker of adverse cardiovascular outcomes.
Strengths and Limitations
We investigated the associations of multiple biomarkers in several candidate biological pathways with LVMi in a relatively large sample of blacks. This ethnic group is at higher risk for hypertension, LVH, and adverse cardiovascular events and has been underrepresented in research studies. Additional studies will be needed to confirm whether these associations are present in other ethnic groups. The crosssectional associations observed in the present study do not allow us to establish causality or temporality. NT-proBNP and MR-proANP are known to be produced by the ventricles, whereas factors leading to higher MR-proADM, CT-proET, and OPG levels need to be established. Given the small number of participants with concentric remodeling and concentric hypertrophy, our study may have been underpowered to detect significant associations between biomarkers and these LV remodeling patterns.
Perspectives
We have demonstrated that higher circulating levels of NT-proBNP, MR-proANP, MR-proADM, CT-proET, and OPG are independently associated with greater LVMi in a large cohort of blacks enriched for hypertension, mainly because of their association with eccentric LVH. Furthermore, adding these biomarkers to age, sex, and conventional risk factors improved the discrimination between those with and without LVH, highlighting their potential clinical value. The results of our study are relevant for better understanding the pathophysiology of LVH and its clinical sequelae in blacks and motivate further investigation to disentangle the roles of natriuretic peptides, adrenomedullin, endothelin, and OPG on cardiac hypertrophy. Furthermore, because LVH is associated with poor prognosis in hypertensives, these biomarkers may aid in identification of individuals at risk of adverse cardiovascular events. Additional studies are necessary to establish whether the natriuretic peptide, adrenomedullin; endothelin; and the OPG/receptor activator of nuclear factor B ligand systems are targets for drug therapy to prevent/reverse LVH.
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